Biohaven (BHVN) drew fresh investor attention today after appointing John Yetimoglu, an AI focused investment leader, to its Board of Directors. The move signals a stronger push into data driven drug discovery and development.

Biohaven’s short term share price return has softened, with the 30 day share price return down 12.35%, although the 90 day share price return is up 38.24% and year to date the share price return is up 25.74%. Over a longer horizon, the 1 year total shareholder return is down 10.51% and the 3 year total shareholder return is down 35.71%. This suggests that recent momentum is building off a weaker multi year experience.

If Biohaven’s AI push has caught your eye, this can be a good moment to broaden your watchlist and check out 42 healthcare AI stocks

Bulls see Biohaven’s AI heavy pipeline and fresh board expertise as a chance to reprice a high growth story. Bears focus on losses and a muted multi year return profile. Which side does the current valuation lean toward?

Biohaven valuation check: what the DCF model is saying

Biohaven is currently trading at $13.63, while the SWS DCF model places its estimate of future cash flow value at $58.37 per share. That gap frames the current debate around the stock.

The SWS DCF model projects future cash flows for Biohaven, then discounts those cash flows back to today to arrive at a present value estimate. It is a way of translating long dated pipeline and revenue expectations into a single number that can be compared with the market price.

For a biopharmaceutical company like Biohaven, which reports a net loss of $647.677m and effectively no revenue, a DCF framework leans heavily on future growth assumptions rather than current earnings. Forecast revenue growth of 67.8% a year, combined with the expectation that the company remains unprofitable over the next three years, makes the timing and scale of eventual cash generation central to this valuation.

Investors also need to weigh this against balance sheet and funding details. Biohaven is assessed as having less than one year of cash runway and relies on higher risk external borrowing for its liabilities. Substantial shareholder dilution over the past year is another factor that can influence how the market treats that $58.37 DCF estimate versus the current $13.63 share price.

Result: DCF fair value of $58.37 (UNDERVALUED)

However, Biohaven still faces clear risks if clinical trial results disappoint or if fresh equity funding further dilutes existing shareholders and reduces the current AI excitement.

Another view on Biohaven’s valuation using market ratios

While the SWS DCF model points to a large gap between Biohaven’s current share price and its estimated cash flow value, the picture is very different when looking at the company’s P/B ratio. Biohaven trades at 15.8x book value, compared with 2.5x for the US Biotechs industry and 5.1x for close peers. That is a very rich premium, which raises the risk that any disappointment on funding, trials or execution could hit the share price hard. Which lens do you trust more right now: the long range cash flow model, or what the market is paying for assets today?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Biohaven for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 51 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Sentiment around Biohaven is clearly mixed, with both risks and potential rewards on the table. It makes sense to review the underlying data yourself and move quickly while the information is fresh. To weigh up both sides in one place, start with the 2 key rewards and 5 important warning signs

Looking for more investment ideas beyond Biohaven?

Do not stop with Biohaven. Broaden your opportunity set with a few focused stock lists that can surface ideas you might otherwise miss.

• Target potential mispricings by scanning companies that combine quality fundamentals with attractive pricing through the 51 high quality undervalued stocks
• Strengthen your capital base by reviewing the 8 dividend fortresses that aim to pair higher yields with resilience.
• Spot early opportunities before the crowd by checking the screener containing 17 high quality undiscovered gems backed by solid financial profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.